MALVERN, PA–(Marketwire – March 11, 2010) – Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL),
a specialty biopharmaceutical company, today announced the managed
distribution network partners that have been contracted to support
XIAFLEXT (collagenase clostridium histolyticum), a novel, first-in-class
biologic for the treatment of adult Dupuytren’s contracture in patients
with a palpable cord.

Further information:

Article source

Related posts:

1. Auxilium Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytren’s Contracture
2. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2009 Financial Results, Guidance for 2010 and Selling Price for XIAFLEX
3. INVO Bioscience Announces the Signing of Distribution Company Delfran Pharmaceuticals and First INVO Babies Born in Colombia
4. Gamma Pharmaceuticals Announces Multi-Year Distribution Agreement With Approximately $48 Million Annualized Minimum Sales Volume
5. The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study